Company: CPMV
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001683168-25-002584
Chunk: 474

Company: Mosaic ImmunoEngineering Inc.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 3
Chunk 474
---
ed consulting 
     –  
     34,333 
  
    Accrued expenses and other 
     5,087  
     56,955 
  
    Net cash used in operating activities 
     (241,159) 
     (497,467)

    Investing activities: 

    Proceeds from redemption of preferred stock of Holocom 
     –  
     433,000 
  
    Net cash provided by investing activities 
     –  
     433,000 

    Financing activities: 

    Proceeds from the issuance of loans payable 
     270,000  
     – 
  
    Payments on loan payables 
     (70,000) 
     – 
  
    Net cash provided by financing activities 
     200,000  
     – 

    Net change in cash and cash equivalents 
     (41,159) 
     (64,467)

    Cash and cash equivalents, beginning of period 
     156,178  
     220,645 

    Cash and cash equivalents, end of period 
    $115,019  
    $156,178 

    Supplemental disclosure of cash flow information: 

    Cash paid for income taxes 
    $2,400  
    $2,400 
  
    Cash paid for interest on loan payable 
    $6,214  
    $– 

See accompanying notes to consolidated financial
statements.

 F-7 

    Mosaic ImmunoEngineering, Inc.

    Notes to Consolidated Financial Statements
    For the Years Ended December 31, 2024 and 2023

Unless the context otherwise requires, references
to the “Company,” “Mosaic,” “we,” “our,” or “us” in this Annual Report on
Form 10-K (“Report”) refer to Mosaic ImmunoEngineering, Inc. and its subsidiaries.

1.        Organization
and Business

Organization

Mosaic ImmunoEngineering, Inc. (the “Company,”
“Mosaic,” “we,” “us,” or “our”) is a corporation organized under Delaware law on March
24, 1992. We are a development-stage biotechnology company focused on advancing and eventually commercializing immunotherapies for the
treatment of cancer. We have historically advanced early-stage product candidate and we are pursuing new product candidates and platforms
to expand our pipeline